Advertisement


Katherine C. Fuh, MD, PhD, on Ovarian Cancer: New Data on Batiraxcept and Paclitaxel

2024 ASCO Annual Meeting

Advertisement

Katherine C. Fuh, MD, PhD, of the University of California, San Francisco, discusses phase III findings of the AXLerate-OC trial, showing that batiraxcept with paclitaxel compared to paclitaxel alone improved progression-free and overall survival in patients with platinum-resistant recurrent ovarian cancer whose tumors were AXL-high in an exploratory analysis (LBA5515).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
So most ovarian cancers will become treatment resistant, in particular platinum resistant. We identified AXL receptor tyrosine kinase that's actually expressed in these platinum-resistant ovarian cancers. A targeted therapy was developed named batiraxcept or AVB-500, which actually is a fusion protein that targets GAS6's ligand. So instead of the GAS6 ligand binding to the membrane AXL receptor, this batiraxcept will bind to that GAS6 ligand so that receptor on the tumor will never be activated. So a phase three trial that we presented talked about GOG-3059 or ENGOT OV-66, AXLerate-OC. This really was focusing on the question, if we give our patients who have platinum-resistant ovarian cancer weekly paclitaxel, which is the standard of care, compared to weekly paclitaxel with batiraxcept, would they actually improve in terms of progression-free survival as a primary endpoint and overall survival as a secondary? We also did perform exploratory endpoints looking at the expression of our tumors for AXL as well as GAS6 and then other exploratory blood markers like serum [inaudible 00:01:15] and GAS6 ratio. Our findings did show that there was similar progression-free survival between those patients who received the standard of care weekly paclitaxel compared to those with batiraxcept with weekly paclitaxel in both progression-free survival and overall survival, about 5 months for PFS and 14 months for OS. When we actually did the exploratory analysis looking at the AXL-high tumors, we did see a difference for those patients who actually had high AXL in their tumor, which is about 80% intensity. They actually benefited from the receiving batiraxcept and paclitaxel compared to paclitaxel alone. We saw this both in progression-free survival and overall survival. So this really leads us to ask the next questions in terms of, can we actually develop perhaps this biomarker for AXL? Can we actually target this biomarker and use this biomarker targeted therapy in the future by using this batiraxcept or another AXL inhibitor in combination with paclitaxel for our patients with platinum-resistant ovarian cancer? So in the future, we would like to see if those patients with high-AXL tumors could actually benefit from an AXL inhibitor in platinum-resistant ovarian cancer and really utilize this AXL expression to help focus in on the patients who actually might not benefit from standard of care and may actually benefit from a combination with the AXL inhibitor.

Related Videos

Gynecologic Cancers

Mostafa Eyada, MD, on Oral Cyclophosphamide Plus Bevacizumab in Recurrent Ovarian Cancer

Mostafa Eyada, MD, of The University of Texas MD Anderson Cancer Center, discusses study results showing that bevacizumab in combination with oral cyclophosphamide had a response rate of 40% in patients with recurrent platinum-resistant high-grade ovarian cancer (Abstract 5517).

Gastroesophageal Cancer

Jens Marquardt, MD, and Jens Hoeppner, MD, on Esophageal Cancer: Phase III Findings on Chemotherapy vs Chemoradiation

Jens Marquardt, MD, of the University of Lübeck, and Jens Hoeppner, MD, of the University of Bielefeld, discuss findings from the ESOPEC trial, which showed that perioperative chemotherapy (fluorouracii, leucovorin, oxaliplatin, docetaxel) and surgery improves survival in patients with resectable esophageal adenocarcinoma when compared with neoadjuvant chemoradiation (41.4 Gy plus carboplatin and paclitaxel) followed by surgery (LBA1).

Multiple Myeloma

Thierry Facon, MD, on Multiple Myeloma: Results From the IMROZ Study on Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone

Thierry Facon, MD, of the University of Lille and Lille University Hospital, discusses phase III findings showing for the first time that isatuximab, an anti-CD38 monoclonal antibody, when given with the standard of care (bortezomib, lenalidomide, dexamethasone, or VRd) to patients with newly diagnosed multiple myeloma who are transplant-ineligible, may reduce the risk of disease progression or death by 40.4% vs VRd alone (Abstract 7500).

Breast Cancer

Pierfranco Conte, MD, on Early-Stage Triple-Negative Breast Cancer: Trial Update on Avelumab as Adjuvant Treatment

Pierfranco Conte, MD, of the University of Padua, discusses phase III findings from the A-BRAVE trial, which was designed to evaluate the efficacy of avelumab, an anti–PD-L1 antibody, as adjuvant treatment for patients with early-stage triple-negative breast cancer who are at high risk (LBA500).

Multiple Myeloma

Suzanne Trudel, MD, on Multiple Myeloma: Results From the DREAMM-8 Study of Treatments After Relapse

Suzanne Trudel, MD, of Canada’s Princess Margaret Cancer Centre, discusses phase III findings showing that, in patients with relapsed or refractory multiple myeloma who had one or more prior lines of treatment, belantamab mafodotin-blmf plus pomalidomide and dexamethasone improved progression-free survival and showed a favorable overall survival trend compared with pomalidomide plus bortezomib and dexamethasone.

Advertisement

Advertisement




Advertisement